Anguraj Moulishankar
Research Subjects
Anguraj Moulishankar has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Gurubasavaraja Swamy Purawarga Matada
Integrated Drug Discovery Center Department of Pharmaceutical Chemistry Acharya & BM Reddy College of Pharmacy Bengaluru Karnataka India
2 shared publications - Manjushree Bv
Department of Pharmaceutical Chemistry, Integrated Drug Discovery Centre Acharya & BM Reddy College of Pharmacy Bengaluru Karnataka India
2 shared publications - Rohit Pal
Integrated Drug Discovery Centre, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru 560107, Karnataka, India
2 shared publications - Sundarrajan Thirugnanasambandam
Department of Pharmaceutical Chemistry, SRM College of Pharmacy, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology Kattankulathur Chengalpattu 603 203 Tamil Nadu India
2 shared publications - Abhishek Ghara
Integrated drug discovery center, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru, India
1 shared publication Dhanalakshmi Mohanradja
Department of Pharmaceutical Analysis, SMVEC Pharmacy College, Madagadipet 605107, Puducherry, India
1 shared publication
Latest Publications
- Open Access
- 8 September 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 108 (3) , e70390
Rational Design, Synthesis, Biological Evaluation, and In Silico Study of N ‐Cinnamamide/Benzamide‐(4‐(Substituted Phenyl)‐6‐(4‐Cyclohexylphenyl)pyrimidin‐2‐yl) Derivatives as EGFR Inhibitors Targeting EGFR WT , EGFR T790M , and EGFR L858R / T790M / C797S in NSCLC
Non‐small cell lung cancer (NSCLC), driven by mutations in the epidermal growth factor receptor (EGFR), presents significant therapeutic challenges, particularly due to drug resistance. This study describes the design, synthesis, and evaluation of a series of novel N ‐Cinnamamide/benzamide‐(4‐(substituted phenyl)‐6‐(4‐cyclohexylphenyl)pyrimidin‐2‐yl) derivatives ( Ri–Rxii ) as EGFR inhibitors. Among these, compound Riv exhibited superior antiproliferative activity against wild‐type and mutant EGFR‐driven NSCLC cell lines, including EGFR L858R/T790M and the drug‐resistant EGFR L858R/T790M/C797S variant, with low IC 50 values and minimal cytotoxicity towards normal cell lines. Compound Riv effectively induced cell cycle arrest at the S and G2/M phases and triggered apoptosis, with 54.38% of cells undergoing apoptotic or necrotic death. Additionally, Riv exhibited strong antioxidant activity, outperforming the standard ascorbic acid in DPPH and ABTS assays, indicating its ability to reduce oxidative stress. Molecular docking and dynamic simulation studies confirmed stable binding interactions with key EGFR residues, and DFT analysis revealed favorable electronic properties. Furthermore, in silico ADMET predictions highlighted Riv 's promising pharmacokinetic and toxicity profiles, supporting its potential as a safe and effective anticancer agent. This comprehensive evaluation positions Riv as a strong candidate for overcoming drug resistance in NSCLC treatment.
- 8 September 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 108 (3) , e70390
Open AccessRational Design, Synthesis, Biological Evaluation, and In Silico Study of N ‐Cinnamamide/Benzamide‐(4‐(Substituted Phenyl)‐6‐(4‐Cyclohexylphenyl)pyrimidin‐2‐yl) Derivatives as EGFR Inhibitors Targeting EGFR WT , EGFR T790M , and EGFR L858R / T790M / C797S in NSCLC
Non‐small cell lung cancer (NSCLC), driven by mutations in the epidermal growth factor receptor (EGFR), presents significant therapeutic challenges, particularly due to drug resistance. This study describes the design, synthesis, and evaluation of a series of novel N ‐Cinnamamide/benzamide‐(4‐(substituted phenyl)‐6‐(4‐cyclohexylphenyl)pyrimidin‐2‐yl) derivatives ( Ri–Rxii ) as EGFR inhibitors. Among these, compound Riv exhibited superior antiproliferative activity against wild‐type and mutant EGFR‐driven NSCLC cell lines, including EGFR L858R/T790M and the drug‐resistant EGFR L858R/T790M/C797S variant, with low IC 50 values and minimal cytotoxicity towards normal cell lines. Compound Riv effectively induced cell cycle arrest at the S and G2/M phases and triggered apoptosis, with 54.38% of cells undergoing apoptotic or necrotic death. Additionally, Riv exhibited strong antioxidant activity, outperforming the standard ascorbic acid in DPPH and ABTS assays, indicating its ability to reduce oxidative stress. Molecular docking and dynamic simulation studies confirmed stable binding interactions with key EGFR residues, and DFT analysis revealed favorable electronic properties. Furthermore, in silico ADMET predictions highlighted Riv 's promising pharmacokinetic and toxicity profiles, supporting its potential as a safe and effective anticancer agent. This comprehensive evaluation positions Riv as a strong candidate for overcoming drug resistance in NSCLC treatment.
- Open Access
- 14 May 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (19) , e01761
Network Pharmacology and Molecular Dynamics Simulation‐Based Elucidation of the Anti‐Alzheimer's Potential of Bacopa Monnieri Phytochemicals
Alzheimer's disease (AD) is a progressive neurological condition marked by cognitive deterioration and restricted treatment alternatives. This study investigated Bacopa monnieri , a traditional medicinal herb recognized for its neuroprotective characteristics, to assess its therapeutic potential against Alzheimer's disease by in silico methods. A network pharmacology approach was utilized to discover targets related to Alzheimer's disease, with CASP3 and APP identified as pivotal nodes. Molecular docking study revealed that three phytochemicals—Luteolin, Apigenin, displayed significant binding affinities for these targets. Moreover, molecular dynamics (MD) simulations confirmed the stability of the ligand–protein interactions throughout time, affirming advantageous conformational behavior. The ADMET study demonstrated satisfactory pharmacokinetic and drug‐likeness characteristics for the phytoconstituents. The results indicate that phytochemicals from B. monnieri , specifically Luteolin and Apigenin, exhibit promise as lead molecules for additional research and development in Alzheimer's disease therapies. Using cutting‐edge computational tools, this study was planned as a thorough in silico investigation that would effectively screen and analyze phytoconstituents and their molecular targets. The results provide a solid basis for upcoming in vitro and in vivo validations, even though the current phase concentrates on computational techniques.
- 14 May 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (19) , e01761
Open AccessNetwork Pharmacology and Molecular Dynamics Simulation‐Based Elucidation of the Anti‐Alzheimer's Potential of Bacopa Monnieri Phytochemicals
Alzheimer's disease (AD) is a progressive neurological condition marked by cognitive deterioration and restricted treatment alternatives. This study investigated Bacopa monnieri , a traditional medicinal herb recognized for its neuroprotective characteristics, to assess its therapeutic potential against Alzheimer's disease by in silico methods. A network pharmacology approach was utilized to discover targets related to Alzheimer's disease, with CASP3 and APP identified as pivotal nodes. Molecular docking study revealed that three phytochemicals—Luteolin, Apigenin, displayed significant binding affinities for these targets. Moreover, molecular dynamics (MD) simulations confirmed the stability of the ligand–protein interactions throughout time, affirming advantageous conformational behavior. The ADMET study demonstrated satisfactory pharmacokinetic and drug‐likeness characteristics for the phytoconstituents. The results indicate that phytochemicals from B. monnieri , specifically Luteolin and Apigenin, exhibit promise as lead molecules for additional research and development in Alzheimer's disease therapies. Using cutting‐edge computational tools, this study was planned as a thorough in silico investigation that would effectively screen and analyze phytoconstituents and their molecular targets. The results provide a solid basis for upcoming in vitro and in vivo validations, even though the current phase concentrates on computational techniques.
- 15 January 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (2)
Multistage Computational Evaluation of Bedaquiline Pyridyl Derivatives: Unveiling Anti‐Tubercular Potential Through QSAR, Molecular Docking, Molecular Dynamics, ADMET, and DFT Analysis
ATP synthase is essential for cellular energy production, and small‐molecule inhibitors of this enzyme have shown significant promise as anti‐tubercular agents. In this study, QSAR analysis was performed using QSARINS to identify potential ATP synthase inhibitors. Among the four developed models, the best‐performing model incorporated seven key descriptors: GATSe3, MinAbsEStateIndex, PEOE_VSA3, MATS7c, VR2_Dzi, VR1_Dzs, and SpMin7_Bhs. The model exhibited strong statistical performance ( R 2 = 0.8518, R 2 adj = 0.8245, RMSE tr = 0.2380, MAE tr = 0.1717, Q 2 LOO = 0.8025, Q 2 F 3 = 0.8097, CCC ext = 0.8798), confirming its robustness and predictive reliability. Based on the validated QSAR model, a series of novel compounds (BP1a–BP1e, BP2a–BP2e, BP3a–BP3e) were designed, and their pMIC 90 values were computationally predicted. BP‐1d emerged as the most promising inhibitor. Molecular docking also showed that the compound BP‐1d with ATP synthase protein had a strong binding affinity (–7.3 kcal/mol), which was better than the reference drug bedaquiline (–6.6 kcal/mol). Molecular dynamics simulations (100 ns) further indicated that BP‐1d forms a more stable enzyme‐ligand complex, maintaining lower RMSD (below 0.5 nm) and consistent hydrogen bonding compared to bedaquiline. Overall, BP‐1d demonstrates strong potential as a lead anti‐tubercular candidate targeting ATP synthase protein.
- 15 January 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (2)
Multistage Computational Evaluation of Bedaquiline Pyridyl Derivatives: Unveiling Anti‐Tubercular Potential Through QSAR, Molecular Docking, Molecular Dynamics, ADMET, and DFT Analysis
ATP synthase is essential for cellular energy production, and small‐molecule inhibitors of this enzyme have shown significant promise as anti‐tubercular agents. In this study, QSAR analysis was performed using QSARINS to identify potential ATP synthase inhibitors. Among the four developed models, the best‐performing model incorporated seven key descriptors: GATSe3, MinAbsEStateIndex, PEOE_VSA3, MATS7c, VR2_Dzi, VR1_Dzs, and SpMin7_Bhs. The model exhibited strong statistical performance ( R 2 = 0.8518, R 2 adj = 0.8245, RMSE tr = 0.2380, MAE tr = 0.1717, Q 2 LOO = 0.8025, Q 2 F 3 = 0.8097, CCC ext = 0.8798), confirming its robustness and predictive reliability. Based on the validated QSAR model, a series of novel compounds (BP1a–BP1e, BP2a–BP2e, BP3a–BP3e) were designed, and their pMIC 90 values were computationally predicted. BP‐1d emerged as the most promising inhibitor. Molecular docking also showed that the compound BP‐1d with ATP synthase protein had a strong binding affinity (–7.3 kcal/mol), which was better than the reference drug bedaquiline (–6.6 kcal/mol). Molecular dynamics simulations (100 ns) further indicated that BP‐1d forms a more stable enzyme‐ligand complex, maintaining lower RMSD (below 0.5 nm) and consistent hydrogen bonding compared to bedaquiline. Overall, BP‐1d demonstrates strong potential as a lead anti‐tubercular candidate targeting ATP synthase protein.
- 10 November 2024
- Published by Elsevier in Acta Tropica
- Vol. 260, 107460
Identification of novel DNA gyrase inhibitor by combined pharmacophore modeling, QSAR analysis, molecular docking, molecular dynamics, ADMET and DFT approaches
- 10 November 2024
- Published by Elsevier in Acta Tropica
- Vol. 260, 107460
Identification of novel DNA gyrase inhibitor by combined pharmacophore modeling, QSAR analysis, molecular docking, molecular dynamics, ADMET and DFT approaches